SEATTLE--(BUSINESS WIRE)--April 3, 2006--Pacific Biometrics, Inc. (OTCBB:PBME, “PBI”) has been awarded a series of contracts with a top multinational pharmaceutical company (the “Sponsor”) to provide essential laboratory data for a global Phase I and Phase II cholesterol-treatment program. These contracts are part of a series of eight contracts related to clinical trials that form part of a global development program for an innovative approach for the prevention and treatment of dyslipidemia, atherosclerosis, and coronary heart disease.
